Table 2.

Ongoing trials targeting the EGFR in glioblastoma

Drugs	Glioblastoma	Phase	Characteristics
D2C7-IT	Recurrent	Phase I	Single-chain fragment variable monoclonal antibody fragment immunotoxin with high binding affinity for both EGFRwt- and EGFRvIII-expressing glioblastoma cells
EGFR(V)-EDV-Dox	Recurrent	Phase I	Nanotechnology delivery system plus panitumumab (monoclonal antibody against EGFR)
ABT-414	Newly diagnosed with EGFR amp	Phase II	Monoclonal antibody-drug conjugate (ADC) against EGFR
ABT-414 + TMZ	Recurrent pediatric	Phase II	Monoclonal antibody-drug conjugate (ADC) against EGFR
anti-EGFRvIII CAR T cells	Recurrent	Phase I	Autologous anti-EGFRvIII CAR-T cells with cyclophosphamide and fludarabine as lymphodepleting chemotherapy
Cetuximab + mannitol + SOC	Newly diagnosed	Phase I/II	Monoclonal antibody against EGFR + brain–blood barrier disruption
ABBV-221	Glioblastoma	Phase I	Antibody-drug conjugate (ADC) targeting EGFR
Tesevatinib	Recurrent	Phase II	Small molecule, ErbB2 receptor antagonist
Rindopepimut	Recurrent	Expended access	Peptide vaccine that targets EGFRvIII
Laptinib + SOC	Recurrent	Phase II	Small molecule, EGFR and ErbB2 inhibitor
Sym004	Recurrent	Phase II	Mixture of two synergistic full-length anti-EGFR antibodies, which bind to two separate non-overlapping epitopes on EGFR
Abemaciclib, CC-115 or neratinib post-SOC	Newly diagnosed	Phase II	CDK4 and 6 inhibitor; DNA-PK/TOR inhibitor; EGFR inhibitor

CAR chimeric antigen receptor, EGFR epidermal growth factor receptor, EGFRwt epidermal growth factor receptor wild-type, TMZ temozolomide, vIII variant III, SOC standard of care